Summary
The quarter was weak on both the top and bottom lines. Revenue fell 8.2% from the prior-year quarter to $4.30 million. Operating loss widened 45.1% to $1.87 million. Net loss widened 22.6% to $1.57 million. Diluted EPS was negative $0.07, down $0.01, so the per-share loss widened. Operating margin was negative 43.4%, down 16.0 percentage points from the prior-year quarter. Management tied the revenue decline primarily to lower software license revenue, with perpetual license sales lumpy because they depend on project timing. Software maintenance revenue moved the other way, helped by subscription-based licenses.
Cost pressure explains why the loss widened faster than revenue fell. Total engineering costs were flat in dollar terms but rose as a share of revenue, according to the filing. Selling and marketing expense increased, driven by higher employee costs and more contracted sales agents. General and administrative expense was steady in dollars. Research and development expense was roughly unchanged. Services and other revenue was flat, and cost of services and other revenue was steady in dollars, though its margin narrowed as a percentage of that revenue. The company expects to keep investing in products and to expand its sales and marketing force. Those choices protect the product roadmap but keep near-term profitability under pressure while revenue is soft.
Cash flow offered a partial offset. Operating cash flow was negative $1.48 million, an improvement of $0.90 million, or 37.6%, from the prior-year quarter. Capital expenditures were $0.02 million. The balance sheet signals were mixed. Deferred revenue rose 15.0% to $3.80 million, while remaining performance obligations fell 20.8% to $1.90 million. That mix leaves conflicting signals on near-term bookings. Interest income rose because of higher rates on U.S. Treasury notes and bonds and corporate bonds, as well as money market accounts. Management also noted that cash, cash equivalents and marketable securities declined from December 31, 2022, primarily because of operating cash use and share repurchases. The company still believes its cash resources are sufficient for at least the next twelve months.
Guidance was limited to cost and interest income commentary. No formal revenue or earnings forecast for the second quarter or full fiscal year was provided. Over the next 12 months, management expects interest income to increase in absolute dollars, with results depending on interest rates and the marketable securities portfolio. For general and administrative expense, management expects absolute dollars to rise but the line to generally decrease as a percentage of net revenues, without tying that outlook to a specific quarter or the full year. Gross margins on services and other revenue are expected to keep fluctuating based on project mix and complexity.
Risks remain centered on revenue timing and the path to profitability. Software license sales depend on winning biometrics projects and on perpetual license timing, which management says can fluctuate. Commercial biometrics markets are emerging, and the company cannot predict future revenue from them. The company maintains a full valuation allowance on its net deferred tax assets and recorded no income tax benefit in the quarter. Inflation has not had a material impact so far, but management warns it could affect future results. If cash resources prove insufficient beyond the next twelve months, the company may need external financing. The quarter showed improving operating cash flow and rising deferred revenue, but the wider operating loss, lower RPO and negative operating margin leave the near-term investment case dependent on better license bookings.
Forecast
No forward guidance in this quarter's filings.
Reported figures
GAAP, from SEC filings| Metric | Q1 FY2023 | Q4 FY2022 | QoQ | Q1 FY2022 | YoY |
|---|---|---|---|---|---|
| Revenue | $4.3M | $4.1M | +6.0% | $4.7M | -8.2% |
| Gross profit | $4.0M | $3.7M | +7.6% | $4.4M | -8.5% |
| Gross margin | 93.1% | 91.6% | +1.5 pp | 93.3% | -0.2 pp |
| Research & development | $2.4M | $2.3M | +3.4% | $2.4M | -1.8% |
| Sales & marketing | $2.0M | $1.9M | +5.1% | $1.8M | +11.8% |
| General & administrative | $1.5M | $1.5M | -2.7% | $1.5M | +2.9% |
| Total operating expenses | $6.2M | $6.1M | +1.5% | $6.0M | +3.2% |
| Operating income (loss) | -$1.9M | -$2.0M | +7.5% | -$1.3M | -45.1% |
| Operating margin | -43.4% | -49.7% | +6.3 pp | -27.4% | -16.0 pp |
| Net income (loss) | -$1.6M | -$1.8M | +10.8% | -$1.3M | -22.6% |
| Net margin | -36.4% | -43.2% | +6.8 pp | -27.3% | -9.2 pp |
| Diluted EPS | -$0.07 | -$0.08 | +$0.01 | -$0.06 | -$0.01 |
Risks
Software license revenue decreased 20% from $2.6 million in the three months ended March 31, 2022 to $2.1 million in the same period in 2023. Management attributes the overall revenue decline and wider operating loss primarily to lower perpetual license sales, which fluctuate based on the timing of customer projects.
Operating loss widened to $1.9 million for the three months ended March 31, 2023 from $1.3 million for the prior-year quarter. Selling and marketing expense increased 12% to $2.0 million, and total engineering costs rose to 62% of total revenue from 58%, while revenue was down 8.2%.
The company is pursuing expansion into new commercial biometrics markets, but management states it is unable to predict future revenue from these emerging markets. This leaves growth prospects uncertain beyond the legacy government biometrics markets.
Remaining performance obligations decreased 20.8% to $1.9 million at March 31, 2023 from $2.4 million at March 31, 2022, which may reduce future revenue visibility. Deferred revenue increased 15.0% to $3.8 million over the same period.
Cash, cash equivalents and marketable securities decreased $2.0 million from December 31, 2022 to $27.3 million at March 31, 2023, driven by $1.5 million of cash used in operating activities and $0.3 million for common stock repurchases. Operating cash flow improved 37.6% versus the prior-year quarter but remained negative at $1.5 million.
Summary, forecast, risks and KPIs are extracted from AWARE INC /MA/'s SEC filings for Q1 FY2023 (10-Q / 10-K and the 8-K earnings release); GAAP figures in the summary are checked against the reported XBRL data. They can contain errors; the filings are authoritative. Processed Oct 2, 2026.